Skip to content

Precigen PGEN Operating Lease Liability Payments - 2026 (Lessee)

Operating Lease Liability Payments - 2026 (Lessee) at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's operating lease liability payments - 2026 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's operating lease liability payments - 2026 (lessee)?
Precigen (PGEN) reported operating lease liability payments - 2026 (lessee) of $1.34M in Q1 2026.
How has Precigen's operating lease liability payments - 2026 (lessee) changed year-over-year?
Precigen's operating lease liability payments - 2026 (lessee) increased by 6.2% year-over-year, from $1.26M to $1.34M.
What does operating lease liability payments - 2026 (lessee) mean?
This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.